Baxter, Inc / Hospira UK Limited’s compounding business and related assets merger inquiry
The CMA investigated and cleared the anticipated acquisition by Baxter, Inc of Hospira UK Limited’s ‘compounding’ business and related assets. Compounding is the process of combining, mixing or altering ingredients to create a medication.
Statutory timetable
| Phase 1 date | Action |
|---|---|
| 13 December 2018 | Decision announced |
| 18 October to 1 November 2018 | Invitation to comment |
| 18 October 2018 | Launch of merger inquiry |
Phase 1
CMA clearance decision
13 December 2018: The CMA has cleared the anticipated acquisition by Baxter International, Inc. of Hospira UK Limited’s compounding business and related assets.
- (4.1.19)
Invitation to comment: Now closed
18 October 2018: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
Launch of merger inquiry
18 October 2018: The CMA announced the launch of its merger inquiry by notice to the parties.
- (18.10.18)
Contact
Please send written representations about any competition issues to:
Updates to this page
Published 18 October 2018Last updated 13 December 2018 + show all updates
-
Clearance decision announced.
-
First published.